Filing Flows › Recursion Pharmaceuticals (RXRX) › Stock forecast & fair value
Recursion Pharmaceuticals (RXRX) stock forecast and price target
Recursion Pharmaceuticals (RXRX) trades at $3.52. 6 analysts' median price target is $7.00 (+99%), from $4.00 to $10.00.
Recursion Pharmaceuticals' latest quarter
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RXRX stock?
The median of 6 analysts' 12-month targets is $7.00, +99% from $3.52; the range is $4.00 to $10.00. The average rating is buy.
Does Recursion Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is RXRX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.